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Prostaglandins Evoke a Whole Variety
of Responses in the Lung
by Philip J. Kadowitz,* Ernst W. Spannhake,*
and Albert L. Hyman*
Rapid intravenous (IV) injections ofthe prostaglandin precursor arachidonic acid (AA) increase pulmo-
nary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in a variety of species. It has
recently been reported that infusions of AA decrease PAP. The purpose of this report is to contrast
responses to bolus injections and infusions of AA in the anesthetized cat. In all experiments rapid IV
injections of AA increased PAP and PVR; however, infusions of 68 to 680 ,ug/min produced variable
responses. In 10of19animals, AA infusion decreased PAPand PVR, and thisresponse wasenhanced when
pulmonary vascular tone was actively increased by vasoconstrictor agentsor alveolar hypoxia. Inthe other
nine animals, the predominant response was an increase in PAP and PVR. In all experiments infusions of
larger amountsofAA (1.4 to 3.4 mg/min) increased PAP. Both pressoranddepressorresponsestoAAwere
inhibited by meclofenamate. This study shows thatinfusion ofsmall amountsofAAdilatesorconstrictsthe
pulmonary vascular bed. In contrast, infusion of larger amounts of AA always causes vasoconstriction.
These data suggest that at low infusion rates, PGI2, which is a vasodilator, is the predominant metabolite
formed from AA in some animals. However, at higher concentrations, the production of constrictor
products predominates. Theseexperimentsalsosuggestthattheproductsformed andtheresponseobserved
may be dependent on a number offactors including the amount oftone present in the pulmonary vascular
bed.
Introduction
In most organ systems including the lung,
arachidonic acid (5, 8, 11, 14-eicosatetraenoic acid)
is converted into the endoperoxide intermediates
PGG2 and PGH2 by a microsomal cyclooxygenase
(1-3). The endoperoxide intermediates (PGG2 and
PGH2) are then converted by terminal enzymes into
primary prostaglandins (PG), thromboxane A2
(TXA2) or prostacyclin, PG12 (2-9). The distribution
and activity ofterminal enzymes determine the pat-
tern of products formed from endoperoxide inter-
mediates in an organ (9-11). Many reports indicate
that the endoperoxide intermediate, endoperoxide
analogs, PGE2, PGF2a, and PGD2 all increase pul-
monary vascular resistance in a variety of species
(10, 12-17). In contrast, PGE2 has dilator activity in
the pulmonary circulation offetal and neonatal ani-
mals (18). The pulmonary vascular effects of TXA2
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are uncertain, but this labile substance has potent
smooth muscle stimulating and platelet aggregating
activity and its breakdown product, TXB2, has mod-
est pressoractivity in the pulmonary vascularbed (7,
19). In contrast to the effects ofPGH2, PGE2, PGD2,
PGF2a,f, and TXB2, the newly discovered metabolite
ofarachidonic acid metabolism, PG12 haspulmonary
vasodilator activity (7, 19). However, the effects of
arachidonic acid on the pulmonary vascular bed are
unclear. Arachidonic acid has been shown to in-
crease pulmonary vascular resistance in a number of
species when injected as a bolus and to contract
isolated segments of pulmonary artery (10, 12, 13,
20-22). These responses are blocked by indometha-
cin suggesting that in the lung arachidonate, when
administered as a bolus is converted to substances
that have pulmonary vasoconstrictor and bron-
choconstrictor activity (10, 12, 13, 21, 22). It has,
however, recently been reported that arachidonic
acid has depressor activity in the pulmonary circula-
tion when the prostaglandin precursor is infused
(12). It has also been recently shown that the newly
discovered bicyclic prostaglandin PG12 dilates that
181feline and canine pulmonary vascular beds (23, 24).
The purpose of the present report is to compare
responses to primary prostaglandins (PGE2, PGF2a,
and PGD2), arachidonic acid, and prostacyclin in the
canine pulmonary vascular bed and the airways.
Methods
The pulmonary vascular effects of primary pros-
taglandins, arachidonic acid and prostacyclin were
investigated in mongrel dogs unselected as to sex
weighing 14.2-24.5 kg. The dogs were anesthetized
with pentobarbital sodium (30 mg/kg, IV) and
strapped to a Philips heart table in the supine posi-
tion. A 6F Edslab thermal dilution catheter was
passed into the main pulmonary artery from the ex-
ternal jugular vein under fluoroscopic guidance
(Philips image intensifier). Pulmonary arterial
pressure was measured from the distal port on the
Edslab catheter. A 7F Teflon catheter was passed
into the left atrium transseptally and large bore cath-
eters were positioned in the aorta from a femoral
artery and in a femoral vein. Cardiac output was
determined with an Edwards thermal dilution com-
puter, model 9500, after injection of 5 ml of 5%
dextrose solution (cooled to 0°C) into the superior
vena cava (proximal port on the Edslab catheter).
Valuesforcardiac outputaveraged 120ml/kgpermin
and compared favorably with cardiac outputs deter-
mined by the indicator-dilution technique in this lab-
oratory. The dogs breathed room air, or room air
enriched with O2, spontaneously through a cuffed
endotracheal tube.
In dogs in which constantflow perfusionofthe left
lower lobe was employed, a specially designed 20F
double-lumen balloon catheter was introduced
through ajugular vein into the arterial branch ofthe
left lower lung lobe under fluoroscopic guidance. A
1.5 mm Teflon catheter with its tip positioned about
2 cm distal to the tip of the perfusion catheter was
used to monitor perfusion pressure in the lobar ar-
tery. Catheters with side holes near the tip were
passed into the main pulmonary artery and femoral
artery and transseptally into a small intrapulmonary
vein and the left atrium. Precautions were taken to
ensure that pressure measurements were made
without wedging in veins 2-3 mm in diameter.
Briefly, a0.9 mmTefloncatheterwithtwo side holes
near the tip was passed through a 3 mm Teflon
catheter that previously had been wedged in a small
intrapulmonary vein. The 0.9 mm catheter was then
withdrawn 1-3 cm from the wedge position until
pressure dropped abruptly. The 0.9 mm catheter
was fixed in place with a Cope adaptor after the
larger catheter had been withdrawn to the left at-
rium. These methods have been described in detail
previously and a diagram ofthe catheterization pro-
cedure is shown in Figure 1 (12, 14). All vascular
pressures were measured with Statham P23D trans-
ducers zeroed at the level of the middle of the right
atrium, and mean pressures were recorded on an
oscilloscopic recorder (model DR-12, Electronics
for Medicine). After all catheters had been posi-
tioned and the dogs heparinized (500 U/kg, IV) the
balloon on the perfusion catheterwasdistended with
2-4 ml of 50% sodium diatrizoate (Hypaque Win-
throp) until pressure in the lobar artery and small
vein decreased to near left atrial pressure. The vas-
cularly isolated left lower lobe then was perfused
with a Sarns roller pump (model 3500) with blood
withdrawn from the right atrium. The pumping rate
was adjusted so that mean pressure in the perfused
lobarartery approximated mean pressure inthe main
pulmonary artery and thereafter was not changed
during the experiment. The pumping rate averaged
260 ml/min. These dogs spontaneously breathed
room air or room air enriched with O2 through a
cuffed endotracheal tube.
Inexperiments in whichthe effectsofthe analogue
on airway pressure were evaluated, the dogs were
FIGURE 1. Diagram showingcatheterization procedure in the dog.
A specially designed 20F balloon catheter is passed into the
artery ofthe lower left lobe and the lung is autoperfused with
the blood withdrawnfrom the rightatrium. Vascularpressures
are measured in the perfused lobar artery, a small pulmonary
lobar vein, and the left atrium and in the main pulmonary
artery and the aorta. The Carlen's endobronchial catheter
permits the left lower and right lungs to be ventilated sepa-
rately.
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(no. 39) and the left lower lobe and right lungs were
ventilated separately with a Harvard dual-cylinder
respiratory (model 618) at a rate of 20 cycles/min
with stroke volumes of 110 ml/min for the left lower
lobe and 280 m/min for the right lungs. The dogs
received succinylcholine chloride (Anectine, Bur-
roughs Wellcome), 2.5 mg/kg, IV, to paralyze ven-
tilation. Translobar airway pressure was measured
with a Statham differential transducer(PM5) bridged
between the left side of the endobronchial divider
and the pleural space and was recorded on the Elec-
tronics for Medicine recorder.
For studies on lung function, mongrel dogs, un-
selected as to sex, weighing from 14.2-18.5 kg, were
anesthetized with chloralose (50 mg/kg) and
urethane (500 mg/kg) administered intravenously.
Polyethylene catheters were advanced from the
femoral artery and vein for the recording of aortic
pressure (PA.) and the administration of drugs, re-
spectively. A 6F Edslab double lumen thermodilu-
tion catheter (Edwards Laboratories) was passed
from the external jugular vein into the main pulmo-
nary artery underfluoroscopic guidance. Pulmonary
arterial pressure (PPA) was measured from the distal
port ofthis catheter. In some experiments, left ven-
tricular end-diastolic pressure was measured
through a Cordis pig-tail catheter advanced from a
femoral arteryor, alternately, left atrial pressure was
measured directly through a 7F Teflon catheter po-
sitioned transseptally in the left atrium. Cardiac out-
put was determined with an Edwards Laboratories
Thermal Dilution Computer, Model 9500A. All vas-
cular pressures were measured with Statham P23BB
or P23AC transducers zeroed at atrial level. Mean
pressures were obtained from the pulsatile signal by
electrical averaging.
The dogs were ventilated with a Harvard ven-
tilator through a short tracheal cannula (2-3 cm di-
ameter) introduced by tracheostomy. Transpulmo-
nary pressurePTPwas measured by a Statham PM5E
differential transducer interposed between the
tracheal cannula and a Harvard pleural cannula in-
serted through the chest wall at the 4th or 5th inter-
costal space. Pneumothorax was adjusted to 10-20
ml immediately afterintroduction ofthe pleural can-
nula. Air flow V was measured with a Fleisch No. 1
pneumotachograph heated above body temperature
andcoupled to a Grass PT5A differential transducer.
PTP and V signals were processed by a Hewlett-
Packard 8816A Respiratory Analyzer which pro-
vided, on line, volume V, dynamic compliance CdYn
and resistance of the lung RL. CdYfl was computed
between points of zero flow by dividing the volume
of each breath by the difference between end-
inspiratory and end-expiratory PTP. RL was com-
puted at early expiration by the method ofMead and
Whittenberger (25) in which instantaneous resistive
pressure was divided by instantaneous flow. Resis-
tive pressure is derived by subtracting the ratio of
volume to computed compliance from PTP. Percent
C02 in end-tidal air was monitored periodically with
a Beckman LB-2 medical gas analyzer connected to
a tap between the respirator and the pneumotacho-
graph. PTP, V, V, RL, CdYfl and vascular pressures
were recorded on a Grass model 7C 8-channel re-
corder. The preparation used to investigate the ef-
fects of the prostaglandins on lung function in the
intact chest dog is illustrated in Figure 2, and this
preparation has been reported on previously (21).
The animals were heparinized with sodium heparin
(Upjohn), 500 Units/kg iv and spontaneousbreathing
was arrested with succinylcholine chloride (Anec-
tine, Burroughs Wellcome), 30-40 mg IV, repeated
as needed. After neuromuscular blockade, incre-
ments of anesthetic were given as needed. Minute
volume was set with tidal volume at 12 ml/kg and the
rate sufficient to maintain end-tidal C02 near5% and
blood gases in a normal range. A lungvolume history
was established by hyperinflating the dog to three
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FIGURE 2. Schematic diagram of the procedure used to evaluate the effects of the prostanoids on lung
function in the intact chest dog.
April 1980 183times the tidal volume 3 min prior to each adminis-
tration of test agent into the superior vena cava
(SVC).
Arachidonic acid (NuChek) 99% pure and in-
domethacin (Merck) were freshly prepared as
sodium salts: arachidonic acid in 10% ethanol in 100
mM sodium carbonate and indomethacin in 100mM
sodium carbonate in normal saline. Prostaglandins
D2, E2, and F2< and the PGH2 analog (Upjohn) were
dissolved in absolute ethanol and stored at -20°C.
Working solutions were freshly prepared in saline.
PGI2 was prepared in20mM Tris buffer, pH 8.5, and
was stored in a freezer.
All values are expressed as the mean + standard
error of the mean unless otherwise indicated. Tests
of significance for group and paired comparisons
were done according to standard statistical methods
(25). Ap value less than 0.05 was considered signifi-
cant.
Results
The pathway for synthesis ofprimary prostaglan-
dins (PGD2, PGE2, and PGF2cG), thromboxane A2
(TXA2), and prostacyclin (PGI2) in the lung is illus-
trated in Figure 3. The fatty acid precursor,
arachidonic acid, is converted into endoperoxide
intermediates by amicrosomal cyclooxygenase. The
endoperoxide intermediates are then converted by
terminal enzymes into prostaglandins, TXA2 or
prostacyclin. Alternatively, the endoperoxides may
be broken down to 12-hydroxyheptadecatrienoic
acid (HHT) and malondialdehyde (MDA), which
have little reported biologic activity. Although the
endogenous precursor is derived from the break-
down of phospholipids in cell membranes, exoge-
nous arachidonic can also serve as substrate for the
cyclooxygenase. The effects of exogenously ad-
ministered arachidonic acid on the pulmonary vas-
cular bed perfused at constant flow are illustrated in
Figure 4. Injection of arachidonic acid, 3 mg, as a
rapidbolus intothe perfused lobarartery produced a
rapid increase in lobar arterial and small vein
pressures but had no effect on left atrial pressure.
The effects ofarachidonic acid on lobar arterial and
venous pressure were dose-related in the range of
doses of 0.1-3 mg and at doses of 1-3 mg aortic
pressure was decreased.
The pressor activities of arachidonic acid, PGE2,
PGF2G,, and a stable endoperoxide (PGH2) analog in
the pulmonary vascular bed under conditions of
controlled flow are compared in Figure 5. PGF2a is
about 10-fold more potent than PGE2, which in turn
is about 10-20 times more active than arachidonic
acid. The stable endoperoxide analog is about 10-
fold more active thanPGF2,. Although not shown on
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FIGURE 3. Diagram showing the pathway for biosynthesis of PGD2, PGF2,,, PGE2, thromboxane A2, and PGI2 in the lung.
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FIGURE 4. Records from an experiment in the intact chest dog,
showingthe effects ofarachidonic acid (3 mg) injected into the
lobar artery on mean pressures in the main pulmonary artery
(Pul. A), the lobar artery (lobar A.), the Aorta, the small
intrapulmonary vein (small v.) and the left atrium (L atrium).
Bloodflow to the left lower lobe was maintained constant with
a pump.
Figure 5, the pressor activities of PGF2a and PGD2
are very similar. In addition to increasing lobar arte-
rial and venous pressures, arachidonic acid in-
creases translobar airway pressure indicating that
the prostaglandin precursor is converted into sub-
stances that have bronchomotor activity in the dog
(Fig. 6). The airway effects ofarachidonic acid were
studied further using the procedure illustrated in
Figure 2. The effects ofarachidonic acid on the air-
ways are depicted in Figure 7. Rapid bolus injection
of 10 mg of the prostaglandin precursor into the
superior vena cava increased transpulmonary
pressure to 200%o of control value. The response
attained a peak within 20 sec and transpulmonary
pressure gradually returned toward control value.
The rise in transpulmonary pressure was accom-
panied by a transient rise in lung resistance and a
greater and more sustained decrease in dynamic
compliance. The effects ofarachidonic acid on lung
function were dose-related and hyperinflation ofthe
lung to total lung capacity 10-15 min after adminis-
tration of the prostaglandin precursor usually re-
turned lung resistance and dynamic compliance to
control levels. The effects of arachidonic acid,
PGD2, and PGF2, on lung function in the intact dog
are compared in Figure 8. All three substances in-
creased pulmonary arterial pressure and lung resis-
tance and decreased dynamic compliance in a dose-
dependent manner. PGD2 was three times more
active than PGF2a in increasing lung resistance and
decreasing lung compliance whereas both prosta-
glandins were more than 1000-fold more active than
arachidonic acid. PGE2 had only small airways
effects in range ofdoses of 1-30 ,g. The stable endo-
peroxide analog and PGD2 had similar effects on the
airways in the intact dog.
The effects ofindomethacin on pulmonary vascu-
lar, airway and systemic vascular responses to
arachidonic acid are illustrated in Figure 9. The in-
creases in transpulmonary pressure, pulmonary
arterial pressure and aortic pressure were abolished
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FIGURE 5. Dose-response curves comparing increases in lobar arterial pressure in response to graded
dosesofanendoperoxide (PGH2)analog, PGF2GX, PGE2, and arachidonicacid. n indicatesthenumber
of animals studied, and blood flow to the left lower lobe was maintained constant with a pump.
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185FIGURE 6. Tracings from anexperiment illustratingtheeffectsofinjection ofarachidonic acid(3 mg)into
the perfused lobar artery on mean vascular pressures inthe lobar artery (lobar a.), the aorta, the left
atrium (L atrium), and on translobar airway pressure. Blood flow to left lower lobe was maintained
constant with a pump and the left lower lobe was ventilated separately using a Carlen's endobron-
chial divider.
5-10 min after administration of indomethacin 2.5-5 rial and small vein pressureswheninj
mg/kg IV. The pulmonary vascular effects of the in doses of 1-10 ,ug into the perfus
newly discovered bicyclic prostaglandin, prosta- Although responses toPGI2 were sm
cyclin (PGI2) are summarized in Table 1. PG1 pro- conditions when tone in the pulmone
duced a small but significant reduction in lobar arte- was minimal, decreases in lobar artc
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FIGURE 7. Record from an experiment illustrating the effects of arachidonic acid (10 mg) on trans-
pulmonary pressure PTP (inspiration up), air flow V, (inspiration upward from zero, expiration
downward), tidal volume V, lungresistanceRL, anddynamic complianceCdYninthe intact chestdog.
Meanpulmonary arterial pressurePPA was increased and mean aortic pressurePAO(not shown in this
figure) was decreased. Injection was made as a bolus into the superior vena cava at the point
indicated.
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FIGURE 8. Dose-response curves comparingeffects ofarachidonic acid (AA), PGD2, and PGF2G, on lung
resistance RL, dynamic compliance CdYn, and pulmonary arterial pressure PPA in intact chest dog.
pressures were substantial when pulmonary vascu-
lar resistance was actively increased (Table 1). In
preliminary studies PGI2 had little effect on the air-
ways in the cat and dog under resting conditions but
decreased transpulmonary pressure when broncho-
motor tone was enhanced.
Discussion
Results of the present study show that when in-
jected as a bolus the prostaglandin precursor,
arachidonic acid, increases lobar arterial and small
vein pressures in the intact dog. Inasmuch as pulmo-
Table 1. Pulmonary vasodilator effects on PGI2 under resting conditions and when pulmonary vascular resistance
is enhanced by infusion of an endoperoxide analog.
Pressure + SE, mm Hg
Lobar artery Small vein Left atrium Aorta
Control 15.9 ± 0.8 10.5 ± 0.6 1.8 ± 0.4 120 ± 5
PGI2, 1-10 ,ug 14.0 ± 1.Oa 9.2 ± 0.6a 1.8 ± 0.4 99 ± 8a
Control + infusion of 11,9-PGH2
analog, 1-5 ,ug/min 31.5 ± 1.3 21.4 ± 1.0 1.7 ± 0.2 125 ± 1.5
PGI2, 1-10 Ag, + infusion of
11,9-PGH2 analog, 1-5 gg/min;
n = 6 25.1 + 2.6a 17.1 ± 1.3 a 1.6 ± 0.2 106 ± 5.2a
ap < 0.05 when compared to corresponding control (paired comparison).
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FIGURE 9. Records from an experiment illustrating the effects of arachidonic acid (6 mg) on transpulmonary pressure PTP, mean
pulmonary arterial pressure PPA and mean aortic pressure PAO (A) before and (B) 20 min after a slow intravenous infusion of
indomethacin, 2.5 mg/kg. At the arrows, arachidonic acid was injected as a bolus into the superior vera cava. Cardiac output in liters
per minute was measured by the thermal dilution technique at the peak of the response.
nary blood flow was held constant and left atrial
pressure was unchanged, the rise in lobar arterial
pressure reflects an increase in pulmonary vascular
resistance. The rise in small vein pressure and in
pressure gradient from the lobar artery to the small
vein suggests that arachidonic acid increases pulmo-
nary vascular resistance by constricting small intra-
pulmonary veins and upstream segments believed to
be small arteries (12). The primary prostaglandins
(PGE2, PDG2, and PGF2,,) as well as PGH2 and a
stable PGH2 analog, all increase pulmonary vascular
resistance in the dog and cat (10, 12-17, 22). Arachi-
donic acid also increased transpulmonary pressure
when the lung was ventilated at constant volume
with a positive pressure ventilator (12). In experi-
ments in which the effects of arachidonic acid on
lung function were further investigated, the increase
in transpulmonary pressure was associated with a
transient rise inlungresistance and a sustainedfall in
dynamic compliance (21). The endoperoxide analog,
PGF2a,f, and PGD2 all increased lung resistance and
decreased dynamic compliance and in this regard
were similar to but much more potent than
arachidonic acid (17, 21, 26). The effects ofPGE2 on
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the pulmonary vascularbed and on the airways were
modest whenthis substance was injected inthe same
doses as PGD2 or PGF2oa (12, 13, 16, 21). Pulmonary
vasoconstrictor, bronchoconstrictor and systemic
vasodepressor responses to arachidonic acid were
blocked after administration of indomethacin, a
cyclooxygenase inhibitor (10-13, 21). These data
suggest that the effects of arachidonic acid on the
airways, pulmonary and peripheral vascular beds is
due to the conversion of the substrate into vaso-
active and bronchoactive metabolites in the cyclo-
oxygenasepathway. The pulmonary vasoconstrictor
response to arachidonic acid is associated with in-
creased synthesis ofE and F "like" prostaglandins,
however; it is not known if PGD2 or TXB2 are pro-
duced bythe lunginthe intactdog(12). The effectsof
arachidonic acid on the pulmonary vascular bed
were not dependent on the presence of platelets or
otherformed elements in that the response to arachi-
donic acid was not diminished when the lung was
perfused with adextran solution (12). These findings
suggest that the substrate is converted to vasoactive
substances by the lung itself and that platelet aggre-
gation or release of vasoactive products from the
Environmental Health Perspectives
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In contrast to the pressor effects ofPGF2a, PGD2,
and PGE2 or the PGH2 analog which may mimic the
effects ofTXA2 on the pulmonary vascular bed, the
newly discovered bicyclic prostaglandin, PGI2, had
vasodilator activity in the pulmonary vascular bed
(23, 24). The pulmonary vasodilator effects of PGI2
were modest under resting conditions but were
greatly enhanced when pulmonary vascular resis-
tance was increased actively by infusion of a vaso-
constrictor substance (23). Although PGI2 had
vasodilator activity, arachidonic acid when admin-
istered as a bolus, consistently increased pulmonary
vascular resistance in the intact dog and cat and in
the isolated dog lung (10, 12, 13, 21, 22). These re-
sults suggest that underphysiologic conditions inthe
intact state, the predominant products formed in the
lungs when arachidonate is injected as a bolus are
vasoconstrictor in nature. Alternatively, it is possi-
ble that both vasoconstrictor and vasodilator
metabolites are formed but that the activity of the
vasoconstrictors overshadows the action of any
simultaneously formed "PGI2-like" substances. It
has been reported that PGI2 is the predominant
metabolite formed from arachidonic acid and endo-
peroxide intermediates in vascular tissue (5, 8, 27).
Indeed, we have observed in some animals that slow
infusions of arachidonic acid decrease pulmonary
vascular resistance in the intact dog and cat. The
explanation for the divergent responses to rapidly
injected arachidonic acid and slowly infused arachi-
donic acid are uncertain at the present time. It is
however possible that, when excessive amounts of
substrate are converted to PGH2, the endothelial
prostacyclin synthetase may be overwhelmed and
the endoperoxide may isomerize to PGD2 and PGE2
or be reduced to PGF2a.
We have reported that administration of cyclo-
oxygenase inhibitors such as indomethacin and
meclofenamate result in a slow gradual increase in
pulmonary vascular resistance in the intactdog (28).
It has been shown that a PGI2-like substance is con-
tinually released by the lung (6). We have, therefore,
suggested that under resting conditions, the pulmo-
nary vascular bed is maintained in a dilated state by
production ofa vasodilator product in the cyclooxy-
genase pathway (28). Recent evidence suggests that
this vasodilator product in the cyclooxygenase
pathway is aPGI2-like substance (6, 23, 24). It would
therefore be ofinterest to ascertain if industrial pol-
lutants such as NO2 or S02 have adverse effects on
enzymes such as cyclooxygenase or prostacyclin
synthetase which function to synthesize PGI2 which
serves to maintain the pulmonary vascular bed in a
dilated state under resting conditions.
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